FDA places partial clinical hold on Bright Minds' BMB-101 Phase 2 epilepsy trial over mouse toxicity
The partial hold pauses a planned seizure study for the Dravet/absence epilepsy candidate after toxicity findings in mice, dimming the small biotech's near-term
scanx.trade · +12 outlets
Eli Lilly's Jaypirca wins FDA approval for first-line CLL/SLL treatment
The label expansion moves the BTK inhibitor into front-line use, expanding its addressable patient population.
scanx.trade · +6 outlets
Gene editing study for Duchenne muscular dystrophy doses first patient
The first-in-human dosing marks a step for in vivo gene editing approaches in a disease with high unmet need.
Stock Titan · +10 outlets
Weight-loss drug pills to go on sale in Australia by Christmas
Oral GLP-1 options reaching shelves widen access beyond injectables in a major market.
AFR · +14 outlets
Weight-loss drug demand pushes Eli Lilly shares to near-record highs
Sustained GLP-1 demand and market forecasts for the obesity category are driving investor enthusiasm around the sector's leaders.
TheStreet · +13 outlets
India's NPPA cancer drug price cuts take effect Nov 9, patients seen saving Rs 2,500-3,500 crore a year
The ceiling price reductions expand affordable access to oncology drugs in India, though experts flag broader pricing concerns.
Livemint · +14 outlets
Seres transplant trial data: bloodstream infections 10% on treatment versus 42.9% on placebo
The microbiome-based therapy cut infection rates in a transplant trial, a potential competitive advantage in a field seeking alternatives to antibiotics.
Stock Titan · +4 outlets
Keytruda biosimilars approach market but face an uphill battle
The loss of exclusivity on Merck's blockbuster opens a biosimilar wave complicated by complex manufacturing and contracting.
BioPharma Dive · +2 outlets
China holds 21 of Asia-Pacific's 30 obesity drug candidates, South Korea follows with six
The pipeline tally highlights China's lead in the regional race to develop alternatives to semaglutide and tirzepatide.
아시아경제 · +3 outlets
Switzerland faces pressure from US drug pricing policy
US efforts to push higher prices onto European payers are rippling into national pricing systems and safety-net programs.
SWI swissinfo.ch · +14 outlets
Valve procedure cut heart failure hospitalizations by over half versus monitoring in trial
The trial result supports interventional treatment in a patient population with limited options.
Stock Titan · +14 outlets
Hanmi's homegrown obesity drug costs about 180,000 won for first 4 weeks, undercutting Mounjaro
The domestic GLP-1 launch prices significantly below imported competitors, intensifying South Korean obesity drug competition.
재경일보 · +5 outlets
Cerus' Phase 3 trial finds treated red blood cells no worse than conventional cells on hemoglobin gains
The non-inferiority result supports the pathogen-reduced blood product ahead of regulatory review.
Stock Titan · +1 outlets
Topical therapy trial for cancer-drug skin reactions to end early after strong interim results
Stopping early for efficacy suggests a potential supportive-care option to keep patients on cancer treatment.
Stock Titan · +6 outlets
South Korean drugmakers turn to CDMO and improved drugs ahead of price cuts
Smaller manufacturers are shifting strategy as government pricing pressure squeezes domestic margins.
BigGo Finance · +1 outlets
AN2 plans blood cancer study after regulatory clearance in three countries
The trial targets a cancer affecting roughly 155,000 people in the US.
Stock Titan · +2 outlets
Hospitals can use children's kidney therapy without joining the study registry
The change broadens real-world access to a pediatric renal therapy outside a registry requirement.
Stock Titan
Dong-A ST launches SK Biopharmaceuticals' epilepsy drug Xcopri in Korea with insurance coverage
The launch expands access to a branded antiseizure medication in the Korean market.
finance.yahoo